A Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

NCT07347938 · clinicaltrials.gov ↗

NOT_YET_RECRUITING

Status

6000

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus

Interventions

DRUG: Siltartoxatug Injection
DRUG: HTIG/TAT/F(ab')₂

Sponsor

Zhuhai Trinomab Pharmaceutical Co., Ltd.